Physician profile
Bobby Simpson
NPI 1972555852
$5,568.20
in general payments reported to CMS, 2019-2025
26 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $528 · 2021: $733 · 2022: $487 · 2023: $224 · 2024: $927 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.10 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,619.54 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $841.31 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $834.42 | 2019-2025 | Ofev, Jascayd |
| Philips North America LLC | $375.91 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy, (8874) Incourage |
| Regeneron Healthcare Solutions, INC. | $323.56 | 2020-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $216.48 | 2019-2024 | Xywav |
| Genzyme Corporation | $209.43 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $188.01 | 2019-2020 | |
| Insmed, INC. | $177.36 | 2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $170.38 | 2025 | Ohtuvayre |
| Amgen INC. | $101.64 | 2022-2025 | Tezspire |
| Avadel Cns Pharmaceuticals, LLC | $98.02 | 2025 | Lumryz |
| Mylan Specialty L.P. | $84.55 | 2019-2022 | |
| Inspire Medical Systems, INC. | $77.52 | 2025 | Inspire |
| Harmony Biosciences LLC | $60.11 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $36.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $20.10 | 2021 | |
| Axsome Therapeutics, INC. | $19.30 | 2025 | Sunosi |
| Allergan, INC. | $17.54 | 2019 | |
| Electromed, INC. | $15.80 | 2024 | Smartvest |
| Inogen, INC. | $14.75 | 2022 | |
| Lilly USA, LLC | $14.71 | 2025 | Zepbound |
| Genentech USA, INC. | $14.29 | 2019 | |
| Fisher & Paykel Healthcare INC | $12.73 | 2020 | |
| 3b Medical, INC. | $12.50 | 2025 | Luna |
| Teva Pharmaceuticals USA, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.